|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ao A, Morrison BJ, Wang H, López JA,
Reynolds BA and Lu J: Response of estrogen receptor-positive breast
cancer tumorspheres to antiestrogen treatments. PLoS One.
6:e188102011. View Article : Google Scholar
|
|
3
|
Shah S and Chen B: Testing for HER2 in
breast cancer: A continuing evolution. Patholog Res Int.
2011:9032022011.
|
|
4
|
Way TD, Kao MC and Lin JK: Apigenin
induces apoptosis through proteasomal degradation of HER2/neu in
HER2/neu-overexpressing breast cancer cells via the
phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem.
279:4479–4489. 2004.
|
|
5
|
Jeong JH, An JY, Kwon YT, Li LY and Lee
YJ: Quercetin-induced ubiquitination and down-regulation of
Her-2/neu. J Cell Biochem. 105:585–595. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee SJ, Yoon JH and Song KS: Chrysin
inhibited stem cell factor (SCF)/c-Kit complex-induced cell
proliferation in human myeloid leukemia cells. Biochem Pharmacol.
74:215–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Huang Q, Ong CN, Yang XF and Shen
HM: Chrysin sensitizes tumor necrosis factor-alpha-induced
apoptosis in human tumor cells via suppression of nuclear
factor-kappaB. Cancer Lett. 293:109–116. 2010. View Article : Google Scholar
|
|
8
|
Khoo BY, Chua SL and Balaram P: Apoptotic
effects of chrysin in human cancer cell lines. Int J Mol Sci.
11:2188–2199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walle T, Otake Y, Brubaker JA, Walle UK
and Halushka PV: Disposition and metabolism of the flavonoid
chrysin in normal volunteers. Br J Clin Pharmacol. 51:143–146.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng X, Meng WD, Xu YY, Cao JG and Qing
FL: Synthesis and anticancer effect of chrysin derivatives. Bioorg
Med Chem Lett. 13:881–884. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ai XH, Zheng X, Tang XQ, Sun L, Zhang YQ,
Qin Y, Liu HQ, Xia H and Cao JG: Induction of apoptosis of human
gastric carcinoma SGC-7901 cell line by 5,
7-dihydroxy-8-nitrochrysin in vitro. World J Gastroenterol.
13:3824–3828. 2007.PubMed/NCBI
|
|
12
|
Yang XH, Zheng X, Cao JG, Xiang HL, Liu F
and Lv Y: 8-Bromo-7-methoxychrysin-induced apoptosis of
hepatocellular carcinoma cells involves ROS and JNK. World J
Gastroenterol. 16:3385–3393. 2010. View Article : Google Scholar
|
|
13
|
Xiao G, Tang X, Yao C and Wang C:
Potentiation of arsenic trioxide-induced apoptosis by
8-bromo-7-methoxychrysin in human leukemia cells involves depletion
of intracellular reduced glutathione. Acta Biochim Biophys Sin
(Shanghai). 43:712–721. 2011. View Article : Google Scholar
|
|
14
|
Koleske AJ, Baltimore D and Lisanti MP:
Reduction of caveolin and caveolae in oncogenically transformed
cells. Proc Natl Acad Sci USA. 92:1381–1385. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao XC, Tian L, Cao JG and Liu F:
Induction of apoptosis by 5,7-dihydroxy-8-nitrochrysin in breast
cancer cells: the role of reactive oxygen species and Akt. Int J
Oncol. 37:1345–1352. 2010.PubMed/NCBI
|
|
16
|
Takahashi-Yanaga F and Sasaguri T:
GSK-3beta regulates cyclin D1 expression: a new target for
chemotherapy. Cell Signal. 20:581–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Steelman LS, Stadelman KM, Chappell WH, et
al: Akt as a therapeutic target in cancer. Expert Opin Ther
Targets. 12:1139–1165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hahn T, Bradley-Dunlop DJ, Hurley LH,
Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG,
Cole BB, et al: The vitamin E analog, alpha-tocopheryloxyacetic
acid enhances the anti-tumor activity of trastuzumab against
HER2/neu-expressing breast cancer. BMC Cancer. 11:4712011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Jin B and Huang C: The PI3K/Akt
pathway and its downstream transcriptional factors as targets for
chemoprevention. Curr Cancer Drug Targets. 7:305–316. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Basso AD, Solit DB, Munster PN and Rosen
N: Ansamycin antibiotics inhibit Akt activation and cyclin D
expression in breast cancer cells that overexpress HER2. Oncogene.
21:1159–1166. 2002. View Article : Google Scholar
|
|
22
|
Priyadarsini RV and Nagini S: Cancer
chemoprevention by dietary phytochemicals: promises and pitfalls.
Curr Pharm Biotechnol. 13:125–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Chen Y and Olopade OI: MYC and
breast cancer. Genes Cancer. 1:629–640. 2010. View Article : Google Scholar
|
|
24
|
Ghatak S, Misra S and Toole BP: Hyaluronan
oligosaccharides inhibit anchorage-independent growth of tumor
cells by suppressing the phosphoinositide 3-kinase/Akt cell
survival pathway. J Biol Chem. 277:38013–38020. 2002. View Article : Google Scholar
|
|
25
|
Millard M, Odde S and Neamati N: Integrin
targeted therapeutics. Theranostics. 1:154–188. 2011. View Article : Google Scholar
|
|
26
|
Menendez JA, Mehmi I, Verma VA, Teng PK
and Lupu R: Pharmacological inhibition of fatty acid synthase
(FAS): a novel therapeutic approach for breast cancer
chemoprevention through its ability to suppress Her-2/neu (erbB-2)
oncogene-induced malignant transformation. Mol Carcinog.
41:164–178. 2004. View
Article : Google Scholar
|
